EGFR and non-small cell lung carcinoma: The results demonstrated that adjuvant EGFR-TKI therapy also resulted in better DFS for resected EGFR-mutant NSCLC patients than adjuvant chemotherapy, with a HR of 0.53 (95% CI, 0.34–0.83; P = 0.006; random effect, I2 = 79.5%; Fig. 2A).